tiprankstipranks
Trending News
More News >

Arcellx, Inc. Reports Q1 2025 Financial Results

Arcellx, Inc. Reports Q1 2025 Financial Results

Arcellx, Inc. ( (ACLX) ) has released its Q1 earnings. Here is a breakdown of the information Arcellx, Inc. presented to its investors.

Confident Investing Starts Here:

Arcellx, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for cancer and other incurable diseases, leveraging its novel synthetic binding scaffold, the D-Domain, to enhance the efficacy and safety of its treatments. In its latest earnings report, Arcellx highlighted a significant net loss of $62.3 million for the first quarter of 2025, compared to a $7.2 million loss in the same period last year, primarily due to increased research and development expenses. The company reported collaboration revenue of $8.1 million, a decrease from $39.3 million in the previous year, reflecting the ongoing development and commercialization efforts with Kite Pharma, a Gilead company. Arcellx’s financial position remains strong with $565.2 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028. Looking ahead, Arcellx continues to advance its clinical trials, including pivotal Phase 2 and Phase 3 trials for its lead product candidate, anito-cel, in collaboration with Kite Pharma, aiming to address unmet medical needs in multiple myeloma and other indications.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1